Evidence map›Paper›PMID 32523892›Full record

ArticleEuropean thyroid journal2020

Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer.

Andrea Palermo, Andrea Napolitano, Daria Maggi, Anda Mihaela Naciu, Gaia Tabacco, Silvia Manfrini, Anna Crescenzi, Chiara Taffon, Francesco Pantano, Bruno Vincenzi and 2 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Andrea PalermoUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
Andrea NapolitanoDepartment of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Daria MaggiUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
Anda Mihaela NaciuUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
Gaia TabaccoUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
Silvia ManfriniUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
Anna CrescenziDepartment of Anatomic Pathology, Campus Bio-Medico University, Rome, Italy.
Chiara TaffonDepartment of Anatomic Pathology, Campus Bio-Medico University, Rome, Italy.
Francesco PantanoDepartment of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Bruno VincenziDepartment of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Guiseppe ToniniDepartment of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Daniele SantiniDepartment of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Università Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors have been recently approved for cancer treatment. Nivolumab is a monoclonal antibody specific for programmed cell death-1 (PD-1) that modulates T-cell response. It was initially used for the treatment of malignant melanoma and then approved in other cancers, such as non-small cell lung cancer and clear cell renal cell carcinoma (ccRCC). So far, the activity of nivolumab in patients with thyroid malignancies has been reported in a single case of anaplastic thyroid cancer. Here, we report the case of a patient with ccRCC who developed a papillary thyroid carcinoma (PTC) under first-line sunitinib treatment. During nivolumab, the second-line treatment for ccRCC, we unexpectedly observed a complete regression of PTC.

Indexed as

CancerImmune checkpoint inhibitorsNivolumabThyroid cancer

Identifiers

PMID32523892
PMCPMC7265713
OpenAlexW3016715028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.